Introduction {#s01}
============

G protein--coupled receptors (GPCRs) are the largest family of membrane proteins and mediate most cellular responses to neurotransmitters, peptide hormones, lipids, and sensory stimuli, as well as therapeutic drugs. The classical role of GPCRs is to couple the binding of ligands to the activation of specific heterotrimeric G proteins, leading to the regulation of downstream effector proteins. Signaling responses are attenuated by desensitization via a series of steps that uncouple GPCR from G proteins and lead to receptor internalization/down-regulation. However, this traditional view has been replaced by a much more complex signaling model. G protein--independent mechanisms and, more recently, signaling from endosomal compartments have been described for several GPCRs ([@bib42]; [@bib35]; [@bib51]).

Corticotropin-releasing hormone (CRH) is a 41-aa peptide that plays a critical role in the integration of neuroendocrine, autonomic, and behavioral responses to stress. Hypothalamic CRH-secreting neurons drive both basal and stress-induced activation of the hypothalamic-pituitary-adrenal (HPA) axis. In addition, CRH is widely distributed in the brain, where it functions as a neuromodulator, integrating a complex system that regulates several aspects of the behavioral stress response. Dysregulation of CRH action through its high-affinity type 1 receptor (CRHR1) is crucial in the pathogenesis of affective disorders ([@bib21]).

CRHR1 is a class B/secretin-like GPCR that, upon ligand activation, signals mainly by Gs coupling, leading to cyclic AMP (cAMP) increase and activation of multiple signaling cascades ([@bib4]). In particular, CRH-stimulated CRHR1 signals through extracellular signal regulated kinase 1/2 (ERK1/2) to induce proopiomelanocortin (*Pomc*) transcription and activate the HPA axis in pituitary corticotrophs and in specific brain structures related to behavioral aspects of stress in response to intracerebroventricular CRH administration ([@bib43]). We have previously described that in a hippocampal neuronal context, CRHR1-mediated ERK1/2 activation triggered by CRH is biphasic, with an early phase peaking at 3--6 min that is dependent on B-Raf and protein kinase A (PKA) and a late phase of sustained ERK1/2 phosphorylation (20--60 min) dependent on CRHR1 internalization and β-arrestin2 ([@bib5]).

The ubiquitous second messenger cAMP regulates numerous, often concurrent, cellular processes. Its activity is tightly regulated and localized to discrete microdomains within the cell to ensure precise spatiotemporal signaling. GPCR-mediated cAMP production was initially thought to depend exclusively on activation of transmembrane adenylyl cyclases (tmACs) at the plasma membrane. More recently, a wealth of research has shown that some activated GPCRs continue to signal by cAMP generation after internalization, thereby defining endocytic cAMP microdomains ([@bib51]). There are nine G protein--regulated tmACs that have different regulatory properties ([@bib54]). Furthermore, a second source of cAMP exists in mammalian cells. Soluble adenylyl cyclase (sAC) is an evolutionarily conserved enzyme that is insensitive to G protein regulation but is directly activated by bicarbonate ([@bib7]) and calcium ions ([@bib25]; [@bib33]). sAC is localized throughout the cell, enabling the production of cAMP in different intracellular locations close to specific cAMP targets ([@bib58]; [@bib48]; [@bib32]).

Combining molecular and pharmacologic tools with Förster resonance energy transfer (FRET)--based biosensor technology, we show that the CRHR1-triggered cAMP response does not exclusively depend on tmACs but also involves sAC as a second source of cAMP. Both cAMP sources play a role in the early ERK1/2 response, but only sAC activity is required for the late ERK1/2 activation phase. Our results indicate that CRH-activated CRHR1 generates cAMP from endocytic compartments. By characterizing the CRHR1 signaling response, we show a functional association between sAC-generated cAMP, ERK1/2 activation, and endosome-based GPCR signaling.

Results {#s02}
=======

sAC contributes to CRHR1-triggered cAMP response in HT22-CRHR1 cells {#s03}
--------------------------------------------------------------------

It is now widely accepted that sAC, which was first identified in testis, is ubiquitously expressed ([@bib48]). RT-PCR results confirmed that sAC mRNA was present in total mouse brain and several mouse cell lines ([Fig. 1 A](#fig1){ref-type="fig"}), including HT22 cells stably expressing CRHR1 (HT22-CRHR1 cells). Using an anti-sAC monoclonal antibody (R21), a 48-kD protein was detected by Western blot in HT22-CRHR1 cells ([Fig. S1 A](http://www.jcb.org/cgi/content/full/jcb.201512075/DC1){#supp1}), and the immunoreactive band was reduced in cells transfected with a sAC-specific siRNA ([Fig. 1 B](#fig1){ref-type="fig"}).

![**Involvement of sAC in CRH-mediated cAMP response.** (A) sAC was detected by RT-PCR in total mouse brain extracts and different mouse cell lines. HPRT was used as control. (B) Depletion of sAC in HT22-CRHR1 cells transfected with siRNA against GL3 (control) or sAC. Western blot developed with sAC monoclonal antibody and total ERK1/2 as a loading control. (C--E) Time course of FRET changes was measured in single HT22-CRHR1-Epac-S^H187^ cells. Cells were stimulated at time 0 with CRH (C and E) or isoproterenol (D). tmAC-specific (100 µM ddA) or sAC-specific (20 µM 2-HE) inhibitors were added 1.5 min after stimulation. Traces are representative of three independent experiments (mean ± SEM, 20--25 cells). (E) Cells were transfected with 50 nM siRNA against GL3 (control) or sAC for 72 h. Inset shows efficiency of sAC knockdown assessed by quantitative RT-PCR normalized to HPRT (mean ± SEM, *n* = 3). \*\*\*, P \< 0.001 by Student's *t* test. (F) Inhibition of cAMP response elicited by CRH or forskolin at the indicated concentrations of ddA or 2-HE. Values represent FRET change 2.5 min after inhibitor addition relative to absence of any inhibitor (mean ± SEM, 15--20 cells).](JCB_201512075_Fig1){#fig1}

We used the FRET-based biosensor Epac-S^H187^, which localizes diffusely throughout the cytoplasm ([@bib27]), to assess CRH-triggered cAMP production at the single-cell level in real time, without phosphodiesterase inhibitors. CRH stimulation of HT22-CRHR1 cells resulted in a rapid increase of intracellular cAMP levels that stayed elevated for at least 40 min after ligand bath application (Fig. S1 B). CRH addition produced a rapid decrease of acceptor emission (cp^173^Venus) and a corresponding increase in donor emission (mTurquoise2), confirming that the observed changes were caused by a FRET reduction, indicating a rise in cytoplasmic cAMP concentration (Fig. S1 B).

When the tmAC-selective inhibitor 2′,5′-dideoxyadenosine (ddA) was added during the time course, the cAMP response was inhibited (P \< 0.001 with respect to control after 5 min) but not completely blocked ([Fig. 1 C](#fig1){ref-type="fig"}). Interestingly, the sAC-specific inhibitor ([@bib3]) 2-hydroxyestradiol (2-HE) also significantly reduced cAMP levels (P \< 0.01 with respect to control after 5 min; [Fig. 1 C](#fig1){ref-type="fig"}). We also determined cAMP content by means of competition with \[^3^H\]cAMP for PKA in HT22-CRHR1 cells preincubated with ddA or sAC-specific inhibitor KH7 ([@bib19]). Both inhibitors significantly reduced the cAMP response triggered by CRH (Fig. S1 C). sAC contribution to the cAMP response triggered by CRH was also indicated by depleting cellular levels of endogenous sAC ([Fig. 1 E](#fig1){ref-type="fig"}).

We tested whether isoproterenol, an agonist of β-adrenergic receptors (which are also Gs coupled), triggered a sAC-dependent cAMP response. We observed that only the tmAC inhibitor significantly affected the cAMP increase elicited by isoproterenol ([Fig. 1 D](#fig1){ref-type="fig"}; P \< 0.001 with respect to control and 2-HE after 5 min), showing that sAC is not a general mediator of the cAMP response generated by GPCRs in the HT22 cellular context. Collectively, our data reveal that sAC is specifically involved in the CRHR1-mediated cAMP response triggered by CRH.

We examined the blocking effect and the specificity of ddA and 2-HE on the cAMP response generated by tmACs and sAC. cAMP responses in cells stimulated with CRH or treated with the tmAC-specific activator forskolin were nearly identical in the presence of ddA ([Fig. 1 F](#fig1){ref-type="fig"}, top), reaching about a 50% inhibition at the highest inhibitor concentration assayed (200 µM). 2-HE concentrations up to 40 µM had no effect on the cAMP response generated by forskolin but caused about a 30% inhibition of the cAMP response to CRH ([Fig. 1 F](#fig1){ref-type="fig"}, bottom). These results indicate that concentrations of 100 µM ddA and 20 µM 2-HE are sufficient to assess and discriminate the contribution of sAC- and tmACs-mediated processes with our experimental approach.

Do tmACs and sAC engage different biochemical cascades? {#s04}
-------------------------------------------------------

Multiple cAMP sources may contribute to a common cAMP pool, or they may act distinctly to elicit specific cellular responses. Having established that, in addition to tmACs, sAC is necessary for the CRH-activated CRHR1 cAMP response, we decided to evaluate whether specific cAMP sources have different biological meanings in CRHR1 signaling. We investigated the role of both cAMP sources in ERK1/2 phosphorylation in HT22-CRHR1 cells. We have previously reported that ERK1/2 can be activated via CRHR1 by both G protein--dependent and --independent mechanisms ([@bib5]).

The dependence of ERK1/2 phosphorylation on different cAMP sources was first assessed using a pharmacologic approach ([Fig. 2 A](#fig2){ref-type="fig"}). As reported previously, specific inhibition of tmACs with ddA attenuated only the CRH-induced early (5 min) ERK1/2 activation phase ([@bib5]). Two pharmacologic inhibitors of sAC, KH7 and 2-HE, reduced pERK1/2 at the early and late time points ([Figs. 2 A](#fig2){ref-type="fig"} and S1 D). When both inhibitors were used in combination, a stronger reduction of pERK1/2 was observed at the early time point ([Fig. 2 A](#fig2){ref-type="fig"}). Furthermore, when the CRH-triggered cAMP response was analyzed with simultaneous addition of both AC inhibitors, a stronger inhibition was observed, further supporting the participation of both cAMP sources in the response ([Fig. 2 B](#fig2){ref-type="fig"}).

![**sAC-generated cAMP has a specific role in CRHR1 signaling.** (A--C) pERK1/2 and total ERK1/2 were measured in HT22-CRHR1 cells stimulated with CRH or isoproterenol for the indicated time points. Results are expressed as the percentage of maximum pERK1/2. (A) Cells were preincubated with vehicle (control) or sAC-specific (7.5 µM KH7) or tmAC-specific (100 µM ddA) inhibitors (mean ± SEM, *n* = 4). Two-way analysis of variance followed by Tukey's test: \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001 with respect to control; \#, P \< 0.05; \#\#\#, P \< 0.01 between indicated treatments. (B) Time course of FRET changes was measured in single HT22-CRHR1-Epac-S^H187^ cells. Cells were stimulated at time 0 with CRH. When indicated, tmAC-specific (100 µM ddA) or sAC-specific (20 µM 2-HE) inhibitors were added. Traces are representative of three independent experiments (mean ± SEM, 20--25 cells). (C) Cells were transfected with 50 nM siRNA against GL3 (control) or sAC for 72 h before stimulation with CRH or isoproterenol (mean ± SEM, *n* = 3). Student's *t* test was performed for each time point. \*, P \< 0.05; \*\*\*, P \< 0.001. Efficiency of sAC knockdown assessed by quantitative RT-PCR normalized to HPRT is shown (mean ± SEM, *n* = 3). \*\*\*, P \< 0.001 by Student's *t* test. (D) CRH neurogenic effect in HT22-CRHR1 cells after 20-h treatment was evaluated in the presence of vehicle (control) or tmAC-specific (50 µM ddA) or sAC-specific (7.5 µM KH7) inhibitors. A representative photograph is shown. Bar, 50 µm. Neurite outgrowth was quantified by repeated-measures one-way analysis of variance followed by Tukey's test (*n* = 3). \*\*\*, P \< 0.001; \*\*, P \< 0.01 with respect to basal.](JCB_201512075_Fig2){#fig2}

Next, we analyzed the time course of CRH-induced ERK1/2 phosphorylation after depleting endogenous sAC ([Fig. 1 B](#fig1){ref-type="fig"}). Knockdown of sAC significantly affected the early but also the late phase of CRH-mediated pERK1/2 ([Fig. 2 C](#fig2){ref-type="fig"}). In HT22-CRHR1 cells, isoproterenol triggered a biphasic ERK1/2 activation response similar to the one described in HEK293 cells ([@bib46]). However, sAC depletion did not affect ERK1/2 phosphorylation triggered by isoproterenol in these cells ([Fig. 2 C](#fig2){ref-type="fig"}), consistent with sAC not being involved in the cAMP response to isoproterenol in HT22-CRHR1 cells ([Fig. 1 D](#fig1){ref-type="fig"}). Interestingly, in these cells, CRH-induced neurite outgrowth was blocked by KH7, but ddA had no effect, showing that the morphologic change requires sAC but not tmACs ([Fig. 2 D](#fig2){ref-type="fig"}). Together, these results show that tmACs and sAC can mediate different functions in CRH signaling.

sAC was identified in a search for B-Raf partners with a potential role in CRH signaling ([@bib5]). B-Raf is the MAPK kinase kinase of the cascade leading to ERK1/2 activation and also acts as a scaffold for assembling signaling complexes. Analysis of CRH-elicited signaling mechanisms reveals that whereas sAC contributes to the cAMP response to a small extent, it has a significant role in the phosphorylation of ERK1/2. Thus, the sAC-generated cAMP pool might be biased toward activation of the ERK1/2 pathway. Consistent with the fact that CRHR1 is a Gs-coupled GPCR, the classic signal transduction mechanism involves the generation of cAMP at the plasma membrane by G protein--regulated tmACs, which is apparent in the early phase of ERK1/2 activation ([@bib5]). The effect of sAC inhibition or depletion on the late phase of pERK1/2 reveals the requirement of CRH-activated sAC in the sustained signaling phase of ERK1/2 activation, suggesting that cAMP is required for ERK1/2 response in the receptor endocytosis-dependent phase.

sAC is involved in CRH signaling in AtT20 corticotrophs but not in 3T3L1-CRHR1 cells {#s05}
------------------------------------------------------------------------------------

Is sAC a specific component of CRHR1 signaling in a hippocampal neuronal context, or does it have a general role in CRHR1 function? To answer this question, we selected the mouse pituitary-derived corticotroph cell line AtT20 as a second physiologically relevant context of CRH action. In AtT20 cells, CRHR1 ([@bib39]) and sAC ([Fig. 1 A](#fig1){ref-type="fig"}) are endogenously expressed, and CRH elicits a transient increase in cAMP levels and activates ERK1/2 ([Fig. S2, A and B](http://www.jcb.org/cgi/content/full/jcb.201512075/DC1){#supp2}).

To determine the involvement of different cAMP sources, we analyzed ERK1/2 activation in response to CRH, which is critical for *Pomc* expression ([@bib30]) and is mediated by cAMP ([@bib50]). Using inhibitors, we found that tmAC-specific ddA, as well as two sAC-selective inhibitors, 2-HE and KH7, impaired CRH-mediated ERK1/2 phosphorylation ([Fig. 3 A](#fig3){ref-type="fig"}). sAC knockdown also significantly reduced CRH-triggered pERK1/2 levels, confirming that sAC participates in CRHR1 signal transduction in AtT20 cells ([Fig. 3 B](#fig3){ref-type="fig"}). In contrast, depletion of sAC had no effect on PACAP38-mediated ERK1/2 activation ([Figs. 3 B](#fig3){ref-type="fig"} and S2 C). Given that PACAP38 also signals through a class B GPCR that generates a cAMP response (Fig. S2 A), these results further highlight that sAC is a specific component of CRHR1 signaling.

![**CRH responses in AtT20 and 3T3L1-CRHR1 cells.** (A) pERK1/2 and total ERK1/2 were measured in AtT20 cells preincubated with vehicle (control) or tmAC-specific (50 µM ddA) or sAC-specific (7.5 µM KH7 or 10 µM 2-HE) inhibitors and stimulated with CRH. (B) pERK1/2 and total ERK1/2 were measured in AtT20 cells transfected with 50 nM siRNA against GL3 (control) or sAC and stimulated with CRH or PACAP38. Results are expressed as the percentage of maximum pERK1/2 (mean ± SEM, *n* = 3). \*, P \< 0.05 by Student's *t* test. Efficiency of sAC knockdown assessed by quantitative RT-PCR normalized to HPRT is shown (mean ± SEM, *n* = 3). \*\*\*, P \< 0.001 by Student's *t* test. (C) Response to CRH in AtT20 cells transiently transfected with *Pomc*--Luc and pretreated with 7.5 µM KH7 or 10 µM 2-HE. Each value was normalized to β-Gal activity (mean ± SEM, *n* = 4 of one representative of three independent experiments with similar results). \*\*\*, P \< 0.001; \*, P \< 0.05 with respect to control by two-way analysis of variance followed by Tukey's test. (D) pERK1/2 and total ERK1/2 of HT22-CRHR1, AtT20, or 3T3L1-CRHR1 cells treated with 8-CPT-cAMP. (E,F) 3T3L1-CRHR1 cells expressing Epac-S^H187^ were stimulated at time 0 with CRH. (F) Cells were transfected with sACt-HA. When indicated, 100 µM ddA or 20 µM 2-HE was added. Time course of FRET changes were measured in single cells. Traces are representative of three independent experiments (mean ± SEM, 20--30 cells).](JCB_201512075_Fig3){#fig3}

We next tested whether sAC was involved in the CRH-mediated activation of *Pomc*, a key CRH target gene in corticotroph cells for HPA axis activation. The transcriptional activity of a *Pomc*--Luc reporter construct ([@bib34]) was significantly decreased in cells pretreated with sAC inhibitors before CRH stimulation, whereas no effects on basal activities were observed ([Fig. 3 C](#fig3){ref-type="fig"}). These findings are consistent with the participation of sAC in a second signaling scenario and suggest that sAC has a key role for CRHR1 action.

We used the mouse fibroblast 3T3L1 cell line stably expressing CRHR1 (3T3L1-CRHR1), which endogenously expresses sAC ([Fig. 1 A](#fig1){ref-type="fig"}), as a third cellular context to explore a role of sAC in CRHR1 signaling. Treatment with the cell membrane--permeable cAMP analog 8-CPT-cAMP enhances ERK1/2 phosphorylation in cells in which ERK1/2 activation is dependent on increased cAMP levels. ERK1/2 response to 8-CPT-cAMP in the three cell lines was determined ([Fig. 3 D](#fig3){ref-type="fig"}). Although CRH activated ERK1/2 and CREB in 3T3L1-CRHR1 cells (Fig. S2 D), pERK1/2 was not linked to increased cAMP levels in this system, unlike in ATt20 and HT22-CRHR1 cells ([Fig. 3 D](#fig3){ref-type="fig"}).

We tested the participation of sAC in 3T3L1-CRHR1 cells by measuring the CRH-mediated cAMP response using the FRET-based biosensor. CRH stimulation triggered a rapid and sustained increase in cAMP levels. Interestingly, whereas the tmAC-selective inhibitor ddA attenuated the cAMP response, the addition of sAC-specific inhibitor 2-HE did not have a significant effect on the cAMP time course ([Fig. 3 E](#fig3){ref-type="fig"}). To rule out the possibility that this result was caused by low sAC expression levels, the experiment was also performed with overexpression of the highly active sACt isoform, with similar results ([Fig. 3 F](#fig3){ref-type="fig"}).

CRH-activated CRHR1 has been shown to trigger an increase in calcium in several cellular contexts ([@bib30]; [@bib16]; [@bib5]). Because calcium activates sAC ([@bib25]; [@bib6]; [@bib28]), we asked whether a CRHR1-dependent calcium response was present in 3T3L1-CRHR1 cells. Using Fluo-4 calcium indicator, we verified that, upon CRH stimulation, there was a calcium increase that could be completely blocked with the extracellular calcium chelator EGTA (Fig. S2 E). In conclusion, despite the fact that CRH-driven responses in 3T3L1-CRHR1 and HT22-CRHR1 cells are comparable in terms of cAMP ([Fig. 1 C](#fig1){ref-type="fig"} and [Fig. 3, E and F](#fig3){ref-type="fig"}) and calcium responses ([@bib5]), sAC is not involved in cAMP generation in 3T3L1-CRHR1 cells. These findings suggest that the involvement of sAC is dependent on the cellular context and that there is a functional association between the sAC-generated cAMP pool and the ERK1/2 pathway.

CRH-stimulated sAC activates PKA and EPACs {#s06}
------------------------------------------

Both PKA and EPACs (cAMP-stimulated guanine nucleotide exchange factors) can trigger the ERK1/2 pathway ([@bib26]). It has been shown that sAC-generated cAMP signals through PKA during capacitation in mammalian sperm ([@bib53]), during leukocyte transendothelial migration ([@bib52]), and in H~2~O~2~-stimulated airway epithelia ([@bib24]), whereas the sAC-EPAC-Rap1 axis has been associated with cell proliferation in prostate and breast cancer cells ([@bib15]; [@bib2]; [@bib38]).

In HT22-CRHR1 cells, pharmacologic inhibition of PKA reduced CRH-mediated early ERK1/2 activation, without affecting late time points ([Fig. 4, A and B](#fig4){ref-type="fig"}). To study PKA activation directly, we expressed the FRET-based PKA activity sensor AKAR4 ([@bib1]; [@bib11]). Preincubation with ddA as well as 2-HE significantly prevented CRH-triggered PKA activation ([Fig. 4 C](#fig4){ref-type="fig"}). Thus, cAMP generated through tmAC and sAC contributes to PKA activity in CRH-stimulated HT22-CRHR1 cells.

![**sAC effectors in HT22-CRHR1 and AtT20 cells.** (A,B,D--F) pERK1/2 and total ERK1/2 were measured in HT22-CRHR1 cells stimulated with CRH for the indicated time points. (A, B, and D) Cells preincubated with vehicle (control), PKA inhibitors (A: 700 nM KT5720; B: 75 µM RpcAMPS), or EPAC-specific inhibitor (5 µM ESI09) were stimulated with CRH. In D, results are expressed as the percentage of maximum pERK1/2 after stimulation under control conditions (mean ± SEM, *n* = 3). \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001 by Student's *t* test. (C) HT22-CRHR1 cells stably expressing AKAR4 were preincubated with tmAC-specific (100 µM ddA) or sAC-specific (20 µM 2-HE) inhibitors and stimulated with CRH at time 0. Time course of FRET changes was measured in single cells. Traces are representative of three independent experiments (mean ± SEM, 20--25 cells). (E and F) Cells were transfected with 50 nM siRNA against GL3 (control), EPAC1, or EPAC2 for 72 h before CRH stimulation. Efficiency of EPAC1 or EPAC2 knockdown assessed by quantitative RT-PCR normalized to HPRT is shown (mean ± SEM, *n* = 3). \*\*\*, P \< 0.001 by Student's *t* test. (G) Cells were transfected with EPAC1 (control) or dominant negative N-EPAC 48 h before CRH stimulation. (H and I) pERK1/2 and total ERK1/2 were measured in AtT20 cells preincubated with vehicle (control), PKA inhibitor (75 µM RpcAMPS; H), or EPAC inhibitor (10 µM ESI09; I) and stimulated with CRH for the indicated times.](JCB_201512075_Fig4){#fig4}

To determine the role of EPACs on CRH action, we used the EPAC1 and EPAC2 inhibitor ESI09 ([@bib57]) at its lowest effective concentration to avoid reported nonspecific effects ([@bib44]). Preincubation with ESI09 strongly reduced CRH-mediated pERK1/2 at both early and late time points ([Fig. 4 D](#fig4){ref-type="fig"}). Genetic silencing of EPAC1 and EPAC2 and transfection with the dominant-negative N-EPAC also diminished ERK1/2 activation ([Fig. 4, E--G](#fig4){ref-type="fig"}). The modest impact of EPAC knockdown may result from incomplete protein depletion. Alternatively, the stronger action of ESI09 or N-EPAC may result from nonspecific effects of these treatments. Therefore, EPACs participate in the activation of ERK1/2 in response to CRH in the hippocampal neuronal context. Moreover, the involvement of EPACs in the sustained phase of ERK1/2 activation further supports that the endocytosis-dependent mechanism of ERK1/2 activation requires cAMP.

In AtT20 cells, CRH-induced ERK1/2 activation was slightly decreased in the presence of the PKA inhibitor RpcAMPS ([Fig. 4 H](#fig4){ref-type="fig"}). Treatment with the EPAC inhibitor impaired pERK1/2 in response to CRH ([Fig. 4 I](#fig4){ref-type="fig"}). Thus, in line with previous studies ([@bib50]), the main cAMP effector underlying CRH-mediated ERK1/2 activation in AtT20 cells is EPAC. Collectively, these results indicate that sAC-generated cAMP does not signal preferentially through a specific cAMP effector, being able to activate both PKA and EPAC in response to CRH.

Endocytosis-dependent cAMP is generated in response to CRH {#s07}
----------------------------------------------------------

CRHR1--β-arrestins interactions are involved in CRHR1 desensitization ([@bib40]; [@bib20]; [@bib37]). We have shown previously that, upon ligand stimulation, CRHR1 is internalized and stays in endocytic compartments 30 min after CRH addition. We examined agonist-induced CRHR1 internalization in HT22-CRHR1 cells. CRH activation promoted a fast internalization of the receptor, with a time course that overlapped that of cAMP production: a significant fraction of CRHR1 was internalized after 5 min and remained constant for at least 30 min of CRH stimulation ([Fig. 5 A](#fig5){ref-type="fig"}). The fact that both the early and late phases of ERK1/2 activation were affected when sAC activity was inhibited or silenced led us to postulate that CRHR1 endocytosis and sAC activity may be linked. To test this hypothesis, we used two experimental approaches to inhibit endocytosis and measured the time course of cAMP accumulation mediated by CRH with the FRET-based biosensor.

![**cAMP response to CRH depends on endocytosis.** (A) Agonist-induced CRHR1 internalization was analyzed by fluorescence flow cytometry at the indicated time points after stimulation by 10 nM CRH in HT22-CRHR1 cells. Fluorescence at time 0 was defined as 100% (mean ± SEM, *n* = 4, 10,000 cells/condition). \*\*\*, P \< 0.001; \*\*, P \< 0.01 with respect to basal by one-way analysis of variance followed by Tukey's test. HT22-CRHR1-Epac-S^H187^ cells were stimulated at time 0 with CRH (B and D) or forskolin (C and E). (B and C) Cells were transfected with pcDNA3 (control) or DynK44A 48 h before stimulation. (D and E) Cells were preincubated with vehicle (control) or 30 µM Dyngo-4a 15 min before stimulation. Time course of FRET changes was measured in single cells (mean ± SEM, *n* = 4). Student's *t* test was performed for each time point. P values in gray; P = 0.05 is indicated with a dotted line.](JCB_201512075_Fig5){#fig5}

First, we used a genetic approach, expressing a dominant-negative mutant of dynamin (DynK44A) that is required for later stages of clathrin-dependent endocytosis. DynK44A blocked CRHR1 internalization upon ligand stimulation ([Fig. S3, A and B](http://www.jcb.org/cgi/content/full/jcb.201512075/DC1){#supp3}) and the sustained ERK1/2 activation phase in HT22-CRHR1 cells ([@bib5]). Cells transfected with DynK44A showed a diminished cAMP response compared with control cells ([Fig. 5 B](#fig5){ref-type="fig"}). Next, we followed a pharmacologic approach using Dyngo-4a, which chemically inhibits dynamin's GTPase activity, blocking endocytosis (Fig. S3, A and C). As in cells expressing DynK44A, the cAMP response to CRH was impaired by Dyngo-4a treatment, showing a profile similar to the one observed with DynK44A ([Fig. 5 D](#fig5){ref-type="fig"}).

The early increase of CRH-mediated cAMP accumulation did not seem to be affected by dynamin-deficient mutant or Dyngo-4a. The differences in the time course of the cAMP response when endocytosis was inhibited were significant 3.5 min after CRH stimulation ([Fig. 5, B and D](#fig5){ref-type="fig"}), in line with fast CRHR1 endocytosis ([Fig. 5 A](#fig5){ref-type="fig"}; [@bib29]; [@bib5]). Importantly, DynK44A expression or Dyngo-4a treatment did not significantly affect the cAMP response elicited by receptor-independent activation of adenylyl cyclases with forskolin ([Fig. 5, C and E](#fig5){ref-type="fig"}), confirming that the effect of endocytosis inhibition required pathway stimulation by the activated receptor.

Changes in the CRH-dependent calcium response cannot be ascribed to a decreased cAMP response in these cells because a similar calcium response was observed in both control and DynK44A-expressing cells (Fig. S3 D). Thus, inhibition of endocytosis produces a significant decrease of cellular cAMP accumulation mediated by CRHR1.

For the class B GPCR PTHR, PTH-triggered cAMP production continues after internalization by a mechanism dependent on receptor interaction with β-arrestins and prolonged ERK1/2 signaling ([@bib12]). We investigated whether activated ERK1/2 was involved in the CRH-cAMP response in HT22-CRHR1 cells. When cells were pretreated with the MEK1/2 inhibitor U0126, a complete blockage of CRH-activated ERK1/2 was observed (Fig. S3 E). However, no differences were found between control and treated cells in the CRH-mediated cAMP response (Fig. S3 F), indicating that cAMP generated by CRH-activated CRHR1 does not depend on ERK1/2 activation.

sAC activity is essential for endocytosis-dependent CRHR1 signaling {#s08}
-------------------------------------------------------------------

We investigated the cAMP source involved in CRHR1 signaling after internalization, combining ACs inhibitors with endocytosis blockage. HT22-CRHR1-Epac-S^H187^ cells transfected with an empty vector or DynK44A mutant (coexpressed with mCherry) were mixed so that both types of cells could be treated, CRH-stimulated, and analyzed in the same microscope field ([Fig. 6 A](#fig6){ref-type="fig"}). When cells were preincubated with vehicle or the tmAC inhibitor ddA, cAMP levels were reduced faster in cells transfected with DynK44A compared with neighboring control cells. However, preincubation with the sAC inhibitor 2-HE led to a loss of the endocytosis effect on the cAMP response to CRH ([Fig. 6 B](#fig6){ref-type="fig"}). This result strongly suggests that the endocytosis-dependent component of the cAMP response is largely dependent on sAC activity. Importantly, 2-HE did not affect CRH-activated CRHR1 endocytosis, as shown by flow cytometry analysis and subcellular localization of CRHR1-GFP ([Fig. 6, C and D](#fig6){ref-type="fig"}).

![**sAC is critical for endosome-generated cAMP in response to CRH.** (A) Schematic representation of the experimental design. HT22-CRHR1-Epac-S^H187^ cells transfected with pcDNA3 (control) or DynK44A plus mCherry for 48 h were pretreated with vehicle (DMSO) or tmAC-specific (100 µM ddA) or sAC-specific (20 µM 2-HE) inhibitors and stimulated with 10 nM CRH. (B) Time course of FRET changes was measured in single cells. The cAMP response is expressed as the percentage of maximum FRET signal obtained in each condition assayed after stimulation (mean ± SEM, *n* = 7). Student's *t* test was performed for each time point. P values in gray; P = 0.05 is indicated with a dotted line. (C and D) Effect of 2-HE on agonist-induced CRHR1 internalization analyzed by fluorescence flow cytometry (C) and cMyc-GFP-CRHR1 subcellular distribution (D). HT22-CRHR1 cells preincubated with vehicle (control) or 20 µM 2-HE were stimulated with 10 nM CRH for the indicated times. (C) Fluorescence measured at time 0 was defined as 100% (mean ± SEM, *n* = 4, 10,000 cells/condition). (D) Representative images obtained for each condition. Arrowheads point to internalized GFP clusters. Bars, 5 µM. (E) pERK1/2 and total ERK1/2 were measured in HT22-CRHR1 cells preincubated with vehicle (control) or sAC-specific (7.5 µM KH7) or endocytosis-specific (30 µM Dyngo-4a) inhibitors and stimulated with CRH. Results are expressed as the percentage of maximum pERK1/2 (mean ± SEM, *n* = 4). Two-way ANOVA followed by Tukey's test: \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001 with respect to control; \#, P \< 0.05 between indicated treatments.](JCB_201512075_Fig6){#fig6}

The differences between CRH-elicited cAMP responses in the presence or absence of a functional endocytosis machinery can be measured for at least 20 min (Fig. S3 G). As a control, when ddA was added after 10 min, cAMP responses were reduced, but the difference in cAMP levels between control and DynK44A cells was maintained (Fig. S6 H). This further indicates that tmACs are still active but are not critical for endocytosis-dependent cAMP generation.

The effect of sAC inhibition and endocytosis blockage on ERK1/2 activation was assessed ([Fig. 6 E](#fig6){ref-type="fig"}). As previously shown ([Fig. 2 A](#fig2){ref-type="fig"}), preincubation with the sAC-specific inhibitor KH7 diminished ERK1/2 activation at early and late time points, whereas the endocytosis inhibitor Dyngo-4a caused a significant reduction of late pERK1/2. Simultaneous inhibition of sAC activity and endocytosis resulted in lower ERK1/2 activation at the early time point compared with Dyngo-4a treatment alone, showing that sAC plays a role in the early endocytosis-independent phase. Remarkably, both treatments, separately or combined, reduced late pERK1/2 to a similar extent, suggesting that sAC activity and endocytosis are involved in the same mechanism that operates at the second signaling phase.

CRH-triggered response depends on sAC modulators: calcium and bicarbonate {#s09}
-------------------------------------------------------------------------

sAC is stimulated by calcium ([@bib25]; [@bib6]; [@bib28]), which may regulate sAC activity in neurons ([@bib56]; [@bib10]). In HT22-CRHR1 cells, CRH elevates intracellular calcium ([@bib5]). To monitor cAMP and calcium responses simultaneously, we used the FRET-based cAMP sensor in combination with a genetically encoded red calcium indicator, REX-GECO1 ([@bib55]). CRH stimulation resulted in rapid and synchronized responses of both second messengers, albeit with different profiles: intracellular calcium increased sharply upon stimulation and returned to basal levels after 60 s, whereas cAMP levels were sustained ([Fig. 7, A and B](#fig7){ref-type="fig"}). Preincubation with the cell-permeable calcium chelator BAPTA-AM reduced pERK1/2 at both early and late time points ([Fig. S4 A](http://www.jcb.org/cgi/content/full/jcb.201512075/DC1){#supp4}), showing that calcium is critical for the ERK1/2 response. Remarkably, the ERK1/2 activation profile in the presence of calcium chelators was reminiscent of the one silencing sAC ([Fig. 2 C](#fig2){ref-type="fig"}).

![**CRH-triggered calcium response regulates cAMP.** (A and B) HT22-CRHR1 cells cotransfected with Epac-S^H187^ and REX-GECO1 were stimulated with 100 nM CRH. (A) Representative images for each signal. Bar, 5 µm. (B) Time course of FRET changes (black trace) or REX-GECO1 fluorescence (orange trace). Data: mean ± SEM, 14 cells. (C) pERK1/2 and total ERK1/2 were measured in HT22-CRHR1 cells transfected with 50 nM siRNA against GL3 (control) or AC1 and stimulated with CRH. Results are expressed as the percentage of maximum pERK1/2 after stimulation under control conditions (mean ± SEM, *n* = 3). \*, P \< 0.05; \*\*, P \< 0.01 by Student's *t* test. Efficiency of AC1 knockdown assessed by quantitative RT-PCR normalized to HPRT is shown (mean ± SEM, *n* = 3). \*\*, P \< 0.01 by Student's *t* test. (D) HT22-CRHR1-Epac-S^H187^ cells preincubated with vehicle (control), 5 µM BAPTA-AM, or 500 µM EGTA were stimulated at time 0 with CRH. Time course of FRET changes was measured in single cells (mean ± SEM, *n* = 3). (E) Calcium response was determined in HT22-CRHR1 cells pretreated with tmAC-specific (100 µM ddA) or sAC-specific (20 µM 2-HE) inhibitors, loaded with Fluo-4-AM, and stimulated at time 0 with 100 nM CRH (mean ± SEM, *n* = 3).](JCB_201512075_Fig7){#fig7}

In addition to sAC, two tmACs (AC1 and AC8) are also positively regulated by calcium ([@bib54]). In accordance with our previous study that the tmAC-specific inhibitor ddA affected only the early phase of ERK1/2 activation ([@bib5]), knockdown of AC1 significantly diminished pERK1/2 at early time points but did not alter the sustained phase ([Fig. 7 C](#fig7){ref-type="fig"}). We could not detect AC8 expression in this system or an effect on the ERK1/2 response using an siRNA against AC8 (Fig. S4, B and C).

If CRH-mediated calcium influx were critical for sAC activation, a reduced cAMP response would be expected when CRH-elicited calcium increase is blocked. CRH-triggered cAMP response was diminished to a similar extent by extracellular EGTA and cell-permeable BAPTA-AM calcium chelators in pretreated HT22-CRHR1 cells ([Fig. 7 D](#fig7){ref-type="fig"}), indicating that the cAMP response depends, at least partially, on a calcium-sensitive mechanism. Notably, the calcium response elicited by CRH was not altered in HT22-CRHR1 cells preincubated with ddA or 2-HE ([Fig. 7 E](#fig7){ref-type="fig"}), suggesting that calcium, required for sAC activity, would not depend on cAMP stimulation by CRH-activated CRHR1.

Next, we examined the effect of the sAC-specific modulator bicarbonate ([@bib47]; [@bib28]) on the ERK1/2 response to CRH. Bicarbonate concentration in the culture medium used to grow cells and perform experiments was 25 mM, which reproduces the bicarbonate concentration in vivo. When we stimulated HT22-CRHR1 cells with CRH in bicarbonate-free medium, ERK1/2 activation was strongly attenuated. Strikingly, the late phase of ERK1/2 activation almost disappeared ([Fig. 8 A](#fig8){ref-type="fig"}).

![**CRH-elicited cAMP response depends on bicarbonate.** (A) HT22-CRHR1 cells were stimulated with CRH in HCO~3~^−^-free or 25 mM HCO~3~^−^ DMEM. (B) HT22-CRHR1 cells preincubated with vehicle (control) or anion channel blocker DIDS were stimulated with CRH. pERK1/2 and total ERK1/2 were measured and expressed as the percentage of maximum pERK1/2 under control conditions (mean ± SEM, *n* = 3). \*, P \< 0.05; \*\*, P \< 0.01 by Student's *t* test. (C) Proposed model: CRH-activated CRHR1 at the plasma membrane generates cAMP and intracellular calcium increase. G protein--dependent tmACs and calcium-activated sAC contribute to cAMP generation, which engages PKA and EPAC in acute ERK1/2 activation (early phase). Rapid CRHR1 internalization leading to G protein--independent sustained ERK1/2 activation (late phase) requires cAMP generated through sAC via EPAC.](JCB_201512075_Fig8){#fig8}

Pharmacologic blockage of anion exchangers with stilbene derivative DIDS modulated bicarbonate levels and sAC activity ([@bib8]). Recently, DIDS has been shown to inhibit sAC by competition with bicarbonate ([@bib28]). CRH-mediated pERK1/2 in the presence of DIDS resulted in a modest decrease of the ERK1/2 response at early time points and almost null ERK1/2 activation at late time points ([Fig. 8 B](#fig8){ref-type="fig"}). By either silencing sAC ([Fig. 2 C](#fig2){ref-type="fig"}) or blocking bicarbonate transport ([Fig. 8 B](#fig8){ref-type="fig"}), we found reduced CRH-dependent ERK1/2 activation, which provides further evidence for a role of bicarbonate-sensitive sAC activity in CRHR1 signaling in HT22-CRHR1 cells.

Collectively, these data are consistent with a mechanism in which CRH-activated sAC is regulated by calcium and bicarbonate and support the notion of sAC activity being required in the late phase of ERK1/2 activation.

Discussion {#s10}
==========

In this study, we demonstrate that sAC is a second source of cAMP in CRHR1 signaling mechanisms elicited by CRH in two physiologically relevant contexts of CRH action. We show that cAMP generated by sAC contributes to the overall cAMP response and that it is critical for ERK1/2 activation upon CRH treatment.

Our work in the hippocampal neuronal context, HT22 cells, also indicates that CRH-activated CRHR1 continues to generate cAMP from endocytic compartments, as recently demonstrated for several GPCRs ([@bib22]; [@bib51]). The study of CRH-activated CRHR1 uncovers a previously unanticipated link between sAC and endosome-based GPCR signaling. These findings revise the canonical model in which GPCR-elicited cAMP production relies solely on tmACs.

A role of sAC in GPCR signaling is just beginning to emerge; only scarce and indirect evidence has been provided so far ([@bib17]; [@bib24]). sAC is unique among the ACs in being activated by bicarbonate and calcium ([@bib25]; [@bib18]). Moreover, unlike tmACs, sAC has no membrane-spanning domains and is distributed throughout the cell. Despite growing evidence that sAC might be responsible for cAMP-mediated functions previously attributed to tmACs, little is known about the mechanisms involved. Here, we identified a key role of CRHR1-induced calcium for sAC activation with both PKA and EPAC effector proteins downstream of sAC ([Fig. 8 C](#fig8){ref-type="fig"}).

In HT22-CRHR1 cells, PKA is involved only in the early ERK1/2 activation phase, whereas EPAC participates in both phases. In the neuroendocrine cell model AtT20, ERK1/2 activation was dependent on both PKA and EPAC. Notably, cAMP and ERK1/2 responses to CRH are short-lived in these cells, resembling the acute phase of pERK1/2 in HT22-CRHR1. Although our data do not rule out an endosome-based CRHR1 signaling mechanism in AtT20 cells, which remains to be explored, they show that ERK1/2 activation requires sAC.

How is sAC physically integrated in signaling complexes at specific cellular locations? Recent work describes a complex assembled by ezrin, an A-kinase anchoring protein that holds sAC at the plasma membrane ([@bib52]). A systematic analysis of sAC interactions will provide insight into specific functions of spatially restricted cAMP pools in cellular responses.

We show that sAC is not a general mediator of GPCRs that activate ERK1/2 downstream of cAMP. Alternative sources of cAMP involved in signaling generated by GPCRs from the endocytic pathway have not yet been explored. Even though sAC is likely to be engaged by a variety of GPCRs, its involvement may depend on specific features of the integral cellular response rather than just the mode of signaling or the cellular context.

β-Arrestins and CRHR1 internalization contribute to ERK1/2 activation in response to CRH, suggesting sustained CRHR1 signaling in endosomes ([@bib5]). Our results show that CRHR1 endocytosis contributes to the overall cAMP response, in line with the emerging paradigm of endosomal generation of cAMP by GPCRs, the mechanisms of which are just beginning to be understood. For the prototypical class A GPCR β-adrenergic receptor 2, the existence of a second phase of Gs coupling from endosomes has been elegantly shown ([@bib23]), whereas for the class B PTHR, a prolonged Gs coupling favored by ERK1/2 and β-arrestin was demonstrated ([@bib12]).

Our present findings reveal a Gs-independent mechanism of cAMP production with an essential role in ligand-activated GPCR endocytosis-mediated signaling. Although there is no doubt that CRHR1 activates G protein--responsive tmACs at the plasma membrane ([@bib41]), our data support a critical contribution of G protein--independent sAC to the cAMP response to CRH that is linked to ERK1/2 activation in cellular contexts of CRHR1 signaling.

Notably, most sustained cAMP responses have been reported for class B GPCRs that mediate the functions of therapeutically relevant peptide hormones ([@bib14]; [@bib13]; [@bib31]; [@bib36]). Future work needs to focus on defining factors that modulate kinetics and spatial organization of the CRHR1-mediated cAMP response, which is thought to have significant physiological implications ([@bib12]; [@bib49]). Furthermore, understanding the role of G protein-- and endosome-dependent signaling, together with the identification of ligands with functional selectivity, may result in clinically valuable tools for pathologies involving the CRH/CRHR1 system.

Materials and methods {#s11}
=====================

Cell culture and transfection {#s12}
-----------------------------

HT22-CRHR1, AtT20, and 3T3-L1-CRHR1 cell lines were cultured in DMEM supplemented with FBS (5% for HT22-CRHR1 and 10% for AtT20 and 3T3-L1-CRHR1), 2 mM [l]{.smallcaps}-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin (Invitrogen) at 37°C in a humidified atmosphere containing 5% CO~2~.

Plasmids were transfected using Lipofectamine and Plus Reagent (Invitrogen) according to the manufacturer's instructions and as previously described ([@bib5]). Experiments were performed 48 h after plasmid transfection. When single-cell measurements were performed in cells transiently transfected with plasmids, cells were cotransfected with a fluorescent protein--expressing plasmid, and only fluorescent cells were used for the studies. siRNA transfection with Lipofectamine 2000 (Invitrogen) was performed as previously described ([@bib5]) and according to the manufacturer's protocol. Experiments were performed 72 h after siRNA transfection. The efficiency of knockdown was assessed by quantitative RT-PCR normalized to HPRT, and experiments with at least 65% reduction of mRNA levels were considered.

Plasmids and siRNA {#s13}
------------------

Plasmids were provided as follows: the mouse CRHR1 expression vectors c-Myc-mCRHR1 and myc-GFP-CRHR1 by J. Deussing (Max Planck Institute of Psychiatry, Munich, Germany); mTurquoise2-EPAC-cp173Venus-Venus (Epac-S^H187^) by K. Jalink (Netherlands Cancer Institute, Amsterdam, Netherlands); AKAR4 by J. Zhang (Johns Hopkins University, Baltimore, MD); REX-GECO1 by R. Campbell (University of Alberta, Edmonton, AB, Canada); the dynamin-K44A expression vector by J. Benovic (Thomas Jefferson University, Philadelphia, PA); mCherry by M. Rossi (Instituto de Investigación en Biomedicina de Buenos Aires, Buenos Aires, Argentina); and EPAC1 and N-EPAC by D.L. Altschuler (University of Pittsburgh School of Medicine, Pittsburgh, PA).

Rat sACfl plasmid was obtained from Addgene (pSAC5.02, plasmid \#16077). A truncated, catalytically active form of sAC (sACt; [@bib48]) tagged with the epitope HA at the C terminus was generated by PCR (sACt-HA). The first 468 aa were amplified via PCR from sACfl using ApaI and NotI restriction sites for N and C termini, respectively, and with the C terminus of sACt and the sequence of the epitope (YPYDVPDYA) encoded in the reverse primer. The insert was ligated into pcDNA3.1(+)/Zeo (Invitrogen).

sAC knockdown was achieved using a 21-nucleotide siRNA (5′-AAUGUAUGGGCUUCAUGGAtt-3′). siRNAs against AC1 and AC8 were purchased from GE Healthcare as pools of four siRNAs (SMART pools; Thermo Fisher Scientific). For EPAC knockdown, the following siRNAs were used: EPAC1 (5′-GGUCAAUUCUGCCGGUGAUtt-3′ and 5′-CGACACCACAGGUUGGAAAtt-3′) and EPAC2 (5′-GCUGGUAGACUGGAUGAUAtt-3′ and 5′-GCUAAUCUACCACACAUUUtt-3′). An siRNA against GL3 (5′-CUUACGCUGAGUACUUCGATT-3′) was used as control.

Generation of stable cell lines {#s14}
-------------------------------

HT22 stable clones expressing cMyc-CRHR1 were previously described ([@bib5]). Stable clones expressing both cMyc-CRHR1 and FRET biosensors (Epac-S^H187^ or AKAR4) were obtained by transfection of HT22-CRHR1 cells with pcDNA3.1/Zeo(+)-Epac-S^H187^ or pcDNA3.1/Zeo(+)-AKAR4 and selection with Zeocin (100 µg/ml; Invitrogen). 3T3-L1 stable clones expressing cMyc-CRHR1 were obtained by transfection of pcDNA3-c-Myc-mCRHR1 and selection with Geneticin (800 µg/ml). In both cases, after 14 d of antibiotic treatment, clonal colonies were isolated and subcultured.

RT-PCR and quantitative real-time PCR {#s15}
-------------------------------------

Total RNA was extracted from cell lines or total mouse brain extracts using TRI reagent (MRC), and complementary DNA synthesis was performed using M-MLV reverse transcription in the presence of RNasin RNase inhibitor (Promega). PCR primers were all intron spanning. cDNAs were amplified using Taq DNA polymerase (Invitrogen). Quantitative real-time PCR was performed with SYBR Green I (Roche) using a CFX96 Touch Real-Time PCR Detection System. Relative expression was calculated for each gene by the Ct method with HPRT for normalization.

Sequences and expected product sizes are as follows: sAC sense 5′-CCTGCATCGCTGTCTGGTAT-3′, antisense 5′-GAACTGTCGGGGTTCTTCGT-3′ (102 bp); AC1 sense 5′-GTGGCCAGTCGGATGGATAG-3′, antisense 5′-TTCACGCTGACTTTGCCTCT-3′ (119 bp); AC8 sense 5′-ACGTCATCATCTTCGCTTCCA-3′, antisense 5′-AGTACTCTGGGTAGGAGCAGA-3′ (150 bp); EPAC1 sense 5′-TCTTACCAGCTAGTGTTCGAGC-3′, antisense 5′-AATGCCGATATAGTCGCAGATG-3′ (223 bp); EPAC2 sense 5′-TAAAAGGCCGTTGGAGCGAT-3′, antisense 5′-GCCAGGACAGCATACCAGTT-3′ (195 bp); HPRT sense 5′-TGGGCTTACCTCACTGCTTTCC-3′, antisense 5′-CCTGGTTCATCATCGCTAATCACG-3′ (139 bp); and β-actin sense 5′-TGACGGGGTCACCCACACTGTGCCCATCTA-3′, antisense 5′-CTAGAAGCATTTGCGGTGGACGATGGAGGG-3′ (663 bp).

Ligand stimulation, drugs, and pharmacological inhibitors {#s16}
---------------------------------------------------------

For MAPK assays, cells were serum-starved for 6 h in OptiMEM before drug pretreatments or stimulation. Cells were stimulated with human/rat CRH (H-2435; Bachem), forskolin (13019; Cayman Chemical), and 8-CPT-cAMP (F1221, Sigma-Aldrich) at the concentrations and time points indicated. After incubation, cells were washed with ice-cold PBS and maintained in ice. When calcium chelators BAPTA-AM (B6769; Thermo Fisher Scientific), EGTA (E3889; Sigma-Aldrich), or pharmacologic inhibitors were used, cells were pretreated with the drugs or vehicle 15--30 min before stimulation. The following inhibitors were used: KT5720 (PKA; K3761; Sigma-Aldrich), RpcAMPS (PKA; 1337; Tocris Bioscience), ddA (tmACs; 288104; EMD Millipore), KH7 (sAC; 3834; Tocris Bioscience), 2-HE (sAC; 13019; Cayman Chemical), DIDS, anion channel blocker (D3514; Sigma-Aldrich), U0126 (MEK; 662005; EMD Millipore), ESI09 (EPAC1/2; SML0814; Sigma-Aldrich), and Dyngo-4a (dynamin; ab120689; Abcam).

For experiments testing bicarbonate dependence, bicarbonate-free DMEM supplemented with 25 mM Hepes was used to prepare media at 0- and 25-mM sodium bicarbonate concentrations. Each condition was adjusted to physiological pH 7.2 with NaOH and HCl and allowed to equilibrate in the incubator for additional 30 min, and then the pH was checked again and adjusted to 7.4. HT22-CRHR1 cells were serum-starved for 6 h in bicarbonate-free DMEM or 25 mM bicarbonate DMEM before stimulation with 10 nM CRH.

Preparation of cellular extracts and immunoblotting {#s17}
---------------------------------------------------

After treatments, cells were washed with ice-cold PBS and lysed in Laemmli sample buffer. Whole-cell lysates were sonicated and heated to 95°C for 5 min. Samples were resolved by SDS-PAGE and transferred to 0.45-mm nitrocellulose membranes (EMD Millipore) for immunoblotting. Membranes were blocked in TBS--Tween 20 (0.05%) containing 5% milk at RT for 1 h under shaking and probed overnight at 4°C with the primary antibodies. The following antibodies were used: anti-sAC (R21; CEP Biotech), anti--c-Myc (9E10; sc-40) and anti--pERK1/2 (E-4; sc-7383) from Santa Cruz Biotechnology, Inc.; anti--total-ERK1/2 (9102; Cell Signaling Technology), anti-phospho CREB (06-519; EMD Millipore), and anti--total-CREB (9104; Cell Signaling Technology).

Chemiluminescent signals were detected by HRP-conjugated secondary antibodies and enhanced chemiluminescence (SuperSignal West Dura; Thermo Fisher Scientific) using a GBOX Chemi XT4 (Syngene). Phosphorylation of MAPK and CREB was detected with the Odyssey Fc Imaging System (LI-COR Biosciences), using anti-mouse-IRDye700DX and anti-rabbit-IRDye800CW secondary antibodies (Rockland). Phosphorylated proteins were relativized to the total protein level, and results were expressed as the percentage of maximum pERK1/2 after stimulation. Immunoreactive signals were analyzed digitally using ImageJ software (National Institutes of Health).

Neurite outgrowth assay {#s18}
-----------------------

HT22-CRHR1 cells seeded at 40% density in 12-well plates were stimulated with 100 nM CRH in the presence of vehicle or tmAC- or sAC-specific inhibitors. After 20 h of treatment, cells were imaged under bright-field illumination using an Olympus IX81 inverted epifluorescence microscope with a 20× air objective and Metamorph software for image acquisition. For each treatment, at least 15 random fields were imaged. Quantification of morphological changes was performed using Simple Neurite Tracer plugin for Fiji software. Neurite outgrowth was determined as the ratio between the longest neurite and the soma diameter per cell after 20 h, measuring at least 100 cells per treatment. For statistical analysis, repeated-measures one-way analysis of variance followed by Tukey's post hoc test (*n* = 3) was performed.

Single-cell intracellular calcium imaging {#s19}
-----------------------------------------

For experiments using ester calcium indicators, cells plated in glass-bottom dishes were loaded for 30--60 min in darkness with 6 µM Fluo-4-AM and 0.14% Pluronic F-127 (Molecular Probes) in Ringer buffer. Images were acquired with a Axio Observer Z1 inverted Epifluorescence microscope (ZEISS), equipped with an AxioCam HRm3 digital CCD camera, a Stage Controller XY STEP SMC 2009 scanning stage, and an Incubator XLmulti S1 (D) and Heating Unit XL S1 (D) for live-imaging incubation. Data acquisition was controlled by Zen Blue 2011 software (ZEISS), configured at a bit depth of 14 bits. Cells were imaged with a 20× air objective (Plan-Apochromat NA 0.8 M27) and illuminated using Colibri.2 470-nm LED excitation (5% power), with a 50-ms exposure acquired every 5 s and a 38HE Filter set for a duration of 10 min. When indicated, cells were preincubated with different reagents. Approximately 30 s after the start of the experiment, CRH was added to a final concentration of 100 nM. Image analysis was performed with Fiji by measuring calcium-dependent changes in fluorescence intensity from resting levels (ΔF/F~0~) in 30--40 cells randomly selected in each experiment.

Spectral FRET and coimaging of cAMP and calcium {#s20}
-----------------------------------------------

HT22-CRHR1, AtT20, or 3T3-CRHR1 cells expressing fluorescent proteins and FRET biosensors were seeded in glass-bottom dishes. Cell imaging was performed on an inverted LSM 710 (ZEISS) equipped with an automated stage, an incubation chamber, and Definite focus system. Data acquisition was performed with ZEN Black 2011 software**.** Images were acquired with a C-Apochromat 40×/1.2 water immersion and temperature-corrected objective lens at 1,024 × 1,024 pixels, 16 bits, pixel dwell time 3.15 µs, with open pinhole (600 µm). The emission spectra of the fluorescent proteins Cerulean, mTurquoise2, Venus, and REX-GECO1 bound to calcium were determined using 405- or 458-nm lasers for the excitation and lambda mode for the detection using a 32-channel QUASAR detector arranged with bandwidth channels of 9.7 nm.

For FRET experiments, cells were illuminated with a 30-mW, 405-nm diode laser at 2% laser power (550--650 gain) and a 405-nm dichroic mirror; emission was collected at 413- to 723-nm wavelengths every 15 s for a duration of 15 min. For coimaging cAMP and calcium dynamics, a 25-mW argon laser for 458-nm excitation (2.5% power, 650 gain) and a 458-nm dichroic mirror were used; emission was collected at 463- to 723-nm wavelengths every 5 s for a duration of 10 min. The saturation level was verified for each image.

For the reference spectra and the experiments, phenol red--free DMEM/F12 medium supplemented with 20 mM Hepes was used, and imaging was performed at 37°C and 5% CO~2~. Approximately 2.5 min after the start of the experiment, CRH was added to the final concentration indicated. When indicated, cells were preincubated for 15 min with different reagents. AC inhibitors were also added after CRH stimulation to evaluate the change in the FRET time course.

For lambda FRET experiments, the linear unmixing tool of ZEN Black 2011 software was used to obtain an image for each fluorophore using the reference spectra. Image quantification was performed with Fiji software. After background subtraction, REX-GECO1, FRET, and donor intensities were measured for single cells for each time point. The FRET/donor ratio or REX-GECO1 intensity was calculated and normalized to resting levels (before stimulation).

Flow cytometry assays {#s21}
---------------------

For CRHR1 surface staining, HT22-CRHR1 cells on 60-mm plates were starved for 1 h in OptiMEM before drug pretreatments or stimulation. When pharmacological inhibitors were used, cells were pretreated with drugs or vehicle 15--30 min before stimulation with CRH for the indicated concentration and time. After incubation, cells were washed with ice-cold PBS and harvested in 1 mM PBS-EDTA. 2.0 × 10^5^ cells were incubated at 4 C with 10% FBS in PBS for 1 h to reduce nonspecific binding. Subsequently, cells were incubated with 0.2 µg anti--c-Myc monoclonal antibody (Santa Cruz Biotechnology, Inc.) for 2 h and, after washing with 1% FBS in PBS, were stained with 1.4 µg anti-mouse Alexa Fluor 647--conjugated secondary antibody (Thermo Fisher Scientific). All solutions contained 0.01% sodium azide. Controls for autofluorescence, primary antibody staining on parental HT22 cells, and secondary antibody staining in absence of primary antibody were performed for each experiment. Flow cytometry data were acquired on a FACsCANTO II (BD). Data were analyzed using FlowJo software (Tree Star).

Confocal microscopy {#s22}
-------------------

HT22-CRHR1 cells transiently transfected with cMyc-GFP-CRHR1 expression vector were seeded on glass coverslips. After treatment, cells were washed with ice-cold PBS, fixed with 4% paraformaldehyde in PBS, permeabilized with 0.01% Triton X-100/PBS, and stained with DAPI. Coverslips were washed with PBS, and cells were mounted with Mowiol and analyzed by confocal microscopy. Images were acquired on an inverted LSM 710. Data acquisition was performed with ZEN Black 2011 software. Images were acquired with a C-Apochromat 63×/1.2 water immersion and temperature-corrected objective lens at 1,024 × 1,024 pixels, 12 bits, pixel dwell time 0.52 µs, with 1 Airy unit. For each treatment, 15--20 individual cells were randomly selected and examined. No fluorescence was observed for control cells transfected with an empty vector.

Competition cAMP binding assay {#s23}
------------------------------

cAMP determination by means of competition with \[^3^H\]cAMP for PKA was performed as previously described ([@bib9]; [@bib5]). In brief, HT22-CRHR1 cells were pretreated for 30 min with the indicated inhibitors, stimulated with CRH, and subjected to ethanol extraction followed by 15-min centrifugation at 3,000 *g*. Supernatants were dried and resuspended in 50 mM Tris-HCl buffer, pH 7.4. cAMP content was determined by means of competition with \[^3^H\]cAMP for PKA and expressed as the percentage of stimulation relative to maximum response. The standard curve was performed using eight cAMP amounts ranging from 0.1 to 90 pmol. Duplicate samples in at least three independent experiments were analyzed.

*Pomc*--Luc reporter assay {#s24}
--------------------------

Luciferase reporter assays were performed as previously described ([@bib45]). In brief, AtT-20 cells were seeded in 48-well plates and transfected with 0.3 µg *Pomc*--Luc and 0.1 µg RSV-Gal (Addgene) for normalization for 3 h using Superfect (QIAGEN) according to the manufacturer's instructions. Transfection mix was replaced with serum-free culture medium overnight. 24 h after transfection, cells were pretreated with vehicle or sAC-specific inhibitors and stimulated with 100 nM CRH for 6 h. Cells were lysed in Passive Lysis Buffer (Promega), followed by measurement of reporter activity according to the manufacturer's instructions (PJK GmbH). Relative Luc values (Luc/β-Gal) were used to normalize for transfection efficiency in all experiments.

Statistics {#s25}
----------

Each experiment was performed at least three independent times. The results are presented as the mean ± SEM of each measurement. Comparisons between treatments were performed using Student's *t* test and one- or two-way analysis of variance (GraphPad Prism) followed by post hoc Tukey's test. Statistically significant differences are indicated.

Online supplemental material {#s26}
----------------------------

Fig. S1 shows the optimization of cAMP measurements by FRET, CRH-triggered cAMP response by competition with \[^3^H\]cAMP for PKA, sAC detection by Western blot, and effect of sAC-specific inhibitors in CRH-mediated ERK1/2 activation. Fig. S2 shows cAMP and ERK1/2 responses triggered by CRH and PACAP38 in AtT20 cells, ERK1/2 and CREB activation, and calcium response to CRH in 3T3L1-CRHR1 cells. Fig. S3 shows CRH-dependent CRHR1 endocytosis blocked by DynK44A and Dyngo-4a, calcium response to CRH when endocytosis is blocked, cAMP and ERK1/2 response in the presence of MEK1/2 inhibitors, and sustained cAMP response in the presence and absence of ddA. Fig. S4 demonstrates the role of calcium in ERK1/2 activation in response to CRH and the expression of AC8 in HT22-CRHR1 cells. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201512075/DC1>.
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